New engineered immune cell therapy tested for tough brain tumors
NCT ID NCT05168423
Summary
This is an early-stage study testing the safety and feasibility of a new type of personalized cell therapy for adults with a specific, aggressive form of recurrent brain cancer called glioblastoma. The therapy involves modifying a patient's own immune cells (T cells) to target two proteins found on the tumor. The main goal is to find the safest dose and see if the treatment can be reliably made and given to patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.